ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 07/25 | 01/27 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
| Recruiting | 3 | 300 | Europe | Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT | UNICANCER, Bayer | Prostate Cancer Metastatic | 03/28 | 09/37 | | |
NCT03927573: Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker |
|
|
| Terminated | 1 | 23 | Europe | GEM3PSCA | AvenCell Europe GmbH, GCP-Service International Ltd. & Co. KG | Non-small Cell Lung Cancer, Prostate Cancer, Renal Cancer, Transitional Cell Carcinoma | 06/23 | 06/23 | | |
NCT04633148: Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker |
|
|
| Terminated | 1 | 16 | Europe | Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA, UniCAR02-T (IMP) | AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH | Prostate Cancer | 03/24 | 03/24 | | |
NCT05999968: Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment |
|
|
| Active, not recruiting | 1 | 10 | Europe, US | Abemaciclib, LY2835219, Darolutamide, LHRH agonist/antagonist | Eli Lilly and Company, Bayer | Prostatic Neoplasms | 02/24 | 07/26 | | |
